Compare Immunovant Inc. Common Stock (IMVT) vs Infosys Limited (INFY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Infosys Limited — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B), while Infosys Limited trades at $10.74 (market cap $41.69B). The key difference: Infosys Limited is far larger — about 6.3× Immunovant Inc. Common Stock's market cap, and Infosys Limited pays a 4.96% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and Infosys Limited for 27 Days on average.
| IMVT | INFY | |
|---|---|---|
Market Cap | $6.62B | $41.69B |
Volume | 1,131,364 | 28,397,442 |
Sector | Health | Technology |
52-Week High | $44.96 | $20.22 |
52-Week Low | $17.03 | $10.49 |
Typical Hold Time | 0 Days | 27 Days |
Enterprise Value | $5.72B | $39.44B |
Dividend Yield | — | 4.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
INFY trades at $10.55, showing no change recently. The stock is in a bearish technical trend, with moving averages signaling sell pressure, while oscillators are neutral. Fundamentally, the company reported $19.28B in revenue for 2025 with a net income margin of 16.37%, and valuation ratios like a P/E of 13.02 suggest relative affordability. Recent news highlights strategic AI collaborations, such as with Columbia University and ABN Amro, aiming to drive innovation. Earnings history is mixed, with a beat in Q1 2026 but a miss in Q2 2026.
The outlook for INFY is cautious, with analyst consensus at a $11.48 price target and a 'Hold' bias (55% of ratings). Opportunities include strong profitability metrics like a 32.12% ROE and AI-driven growth initiatives, but risks involve bearish technical signals, potential earnings volatility, and competitive pressures in IT services. Net cash flow turned negative in 2026, indicating financial strain, which could limit upside near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →
